Intensive chemotherapy with high-dose epirubicin every 2 weeks and prophylactic administration of filgrastim in XXXX .

@entity1 @entity137 @entity3136 @entity0 @entity1259 @entity1370 @entity221
50 @entity1 with @entity0 were treated with an intensified regimen which consisted of high-dose @entity1259 (110 mg/m2) every 2 weeks and filgrastim (5 micrograms/kg) subcutaneously for 13 days, starting 24 h after chemotherapy. 44 @entity1 completed all six cycles. The median interval between cycles of treatment was 14.3 days. The actually administered median dose per unit time per @entity1 was 53 mg/m2/week, amounting to 97.2% of the dose prescribed by the protocol. 7 [14%, 95% confidence interval (C.I.) 4-24%] @entity1 achieved a complete and 25 (50%, 95% C.I. 36-64%) a partial response. Median time to progression was 32 weeks and median survival 64 weeks. @entity3136 and @entity221 each occurred in 7 (14%) @entity1 . Grade 3 haematological @entity137 was observed in 6 (12%) @entity1 . 1 (2%) @entity1 developed grade 4 @entity1370 . This intensified regimen appears to be a well tolerated and effective treatment in @entity0 .
